Spotlight on the relevance of mtDNA in cancer

• A. Cruz-Bermúdez ^[1] ; R. J. Vicente-Blanco ^[1] ; E. Gonzalez-Vioque ^[2] ; M. Provencio ^[2] ; M. Á. Fernández-Moreno ^[1] ; R. Garesse ^[1]
  1. [1] Universidad Autónoma de Madrid

     Universidad Autónoma de Madrid

     Madrid, España

     
  2. [2] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 4 (April 2017), 2017, págs. 409-418
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The potential role of the mitochondrial genome has recently attracted interest because of its high mutation frequency in tumors. Different aspects of mtDNA make it relevant for cancer‘s biology, such as it encodes a limited but essential number of genes for OXPHOS biogenesis, it is particularly susceptible to mutations, and its copy number can vary. Moreover, most ROS in mitochondria are produced by the electron transport chain. These characteristics place the mtDNA in the center of multiple signaling pathways, known as mitochondrial retrograde signaling, which modifies numerous key processes in cancer. Cybrid studies support that mtDNA mutations are relevant and exert their effect through a modification of OXPHOS function and ROS production. However, there is still much controversy regarding the clinical relevance of mtDNA mutations. New studies should focus more on OXPHOS dysfunction associated with a specific mutational signature rather than the presence of mutations in the mtDNA.